Scientific Reports (May 2024)

GGT1 is a SNP eQTL gene involved in STAT3 activation and associated with the development of Post-ERCP pancreatitis

  • Ryutaro Furukawa,
  • Masaki Kuwatani,
  • Jing-Jing Jiang,
  • Yuki Tanaka,
  • Rie Hasebe,
  • Kaoru Murakami,
  • Kumiko Tanaka,
  • Noriyuki Hirata,
  • Izuru Ohki,
  • Ikuko Takahashi,
  • Takeshi Yamasaki,
  • Yuta Shinohara,
  • Shunichiro Nozawa,
  • Shintaro Hojyo,
  • Shimpei I. Kubota,
  • Shigeru Hashimoto,
  • Satoshi Hirano,
  • Naoya Sakamoto,
  • Masaaki Murakami

DOI
https://doi.org/10.1038/s41598-024-60312-2
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Post-ERCP pancreatitis (PEP) is an acute pancreatitis caused by endoscopic-retrograde-cholangiopancreatography (ERCP). About 10% of patients develop PEP after ERCP. Here we show that gamma-glutamyltransferase 1 (GGT1)-SNP rs5751901 is an eQTL in pancreatic cells associated with PEP and a positive regulator of the IL-6 amplifier. More PEP patients had the GGT1 SNP rs5751901 risk allele (C) than that of non-PEP patients at Hokkaido University Hospital. Additionally, GGT1 expression and IL-6 amplifier activation were increased in PEP pancreas samples with the risk allele. A mechanistic analysis showed that IL-6-mediated STAT3 nuclear translocation and STAT3 phosphorylation were suppressed in GGT1-deficient cells. Furthermore, GGT1 directly associated with gp130, the signal-transducer of IL-6. Importantly, GGT1-deficiency suppressed inflammation development in a STAT3/NF-κB-dependent disease model. Thus, the risk allele of GGT1-SNP rs5751901 is involved in the pathogenesis of PEP via IL-6 amplifier activation. Therefore, the GGT1-STAT3 axis in pancreas may be a prognosis marker and therapeutic target for PEP.